

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6331796

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
WALTER CABRI	11/17/2017
SASWATA LAHIRI	12/04/2017
BHUWAN BHASKAR MISHRA	12/04/2017
ABUL AZIM	12/04/2017
NILENDU PANDA	12/04/2017
POLI REDDY BHAVANAM	12/04/2017
KRISHANU RAY	12/04/2017
NIKUNJ KACHHADIA	12/04/2017
KUMBER SINGH	12/04/2017
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	FRESENIUS KABI ONCOLOGY LTD.
<b>Street Address:</b>	B-310, SOM DATT CHAMBERS-I
<b>Internal Address:</b>	BHIKAJI CAMA PLACE
<b>City:</b>	NEW DELHI
<b>State/Country:</b>	INDIA
<b>Postal Code:</b>	110 066
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	17061111
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(312)616-5700
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	312-616-5600
<b>Email:</b>	assignments@leydig.com
<b>Correspondent Name:</b>	LEYDIG, VOIT & MAYER, LTD.
<b>Address Line 1:</b>	TWO PRUDENTIAL PLAZA, STE. 4900
<b>Address Line 2:</b>	180 N. STETSON
<b>Address Line 4:</b>	CHICAGO, ILLINOIS 60601-6731
<b>ATTORNEY DOCKET NUMBER:</b>	750521

PATENT

<b>NAME OF SUBMITTER:</b>	KENNETH P. SPINA
<b>SIGNATURE:</b>	/Ken Spina/
<b>DATE SIGNED:</b>	10/01/2020
<b>Total Attachments: 4</b> source=Assignment#page1.tif source=Assignment#page2.tif source=Assignment#page3.tif source=Assignment#page4.tif	

ASSIGNMENT

WHEREAS, I/WE

(1) Walter CABRI of c/o Fresenius Kabi Anti-Infectives, Piazza Maestri del Lavoro, 7 20063 Cernusco sul Naviglio - Milano, Milano, Italy,

(2) Saswata LAHIRI of c/o Fresenius Kabi Oncology Limited, Echelon Institutional Area, Plot No -- 11, Sector-32, Gurgaon-122001, Haryana, India Gurgaon, India,

(3) Bhurwan Bhaskar MISHRA of c/o Fresenius Kabi Oncology Limited, Echelon Institutional Area, Plot No -- 11, Sector-32, Gurgaon-122001, Haryana, India Gurgaon, India,

(4) Abul AZIM of c/o Fresenius Kabi Oncology Limited, Echelon Institutional Area, Plot No -- 11, Sector-32, Gurgaon-122001, Haryana, India Gurgaon, India,

(5) Nilendu PANDA of c/o Fresenius Kabi Oncology Limited, Echelon Institutional Area, Plot No -- 11, Sector-32, Gurgaon-122001, Haryana, India Gurgaon, India,

(6) Poli Reddy BHAVANAM of c/o Fresenius Kabi Oncology Limited, Echelon Institutional Area, Plot No -- 11, Sector-32, Gurgaon-122001, Haryana, India Gurgaon, India,

(7) Krishanu RAY of c/o Fresenius Kabi Oncology Limited, Echelon Institutional Area, Plot No -- 11, Sector-32, Gurgaon-122001, Haryana, India Gurgaon, India,

(8) Nikunj KACHHADIA of c/o Fresenius Kabi Oncology Limited, Echelon Institutional Area, Plot No -- 11, Sector-32, Gurgaon-122001, Haryana, India Gurgaon, India, and

(9) Kumber SINGH of c/o Fresenius Kabi Oncology Limited, Echelon Institutional Area, Plot No -- 11, Sector-32, Gurgaon-122001, Haryana, India Gurgaon, India,

hereinafter referred to as Assignor, have invented a certain invention entitled:

POLYMORPHIC FORMS OF AFATINIB FREE BASE AND AFATINIB DIMALEATE

for which International Patent Application No. PCT/IB2016/053420 has been filed on June 10, 2016, and

WHEREAS, FRESENIUS KABI ONCOLOGY LTD., of B -- 310, Som Datt Chambers -- I, Bhikaji Cama Place, New Delhi 110 066, India, hereinafter referred to as Assignee, is desirous of acquiring the entire U.S. right, title, and interest of Assignor in, to, and under the invention and the referenced International Patent Application, including the entire right, title, and interest of Assignor in, to, and under the U.S. national phase thereof, filed on December 12, 2017, under U.S. Application No. 15/735,855, and

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,

Assignor assigns and transfers to Assignee and Assignee's legal representatives, successors, and assigns the entire right, title, and interest in, to, and under the invention, the referenced patent application, other such applications (e.g., provisional applications, non-

provisional applications, continuations, continuations-in-part, divisionals, reissues, reexaminations, national and regional phase applications, petty patent applications, and utility model applications) that may be filed in the U.S. and/or any country foreign to the U.S. on the invention, the patents that may issue thereon, and the patents as may be modified as the result of applicable procedures (e.g., supplemental examinations, ex parte reexaminations, inter partes reexaminations, inter partes reviews, post-grant reviews, and oppositions),

Assignor conveys to the Assignee the right to make applications in Assignee's own behalf for protection of the invention in the U.S. and countries foreign to the U.S. and to claim priority to the referenced patent application and other such applications that may be filed in the U.S. or any country foreign to the U.S. on the invention under the Patent Cooperation Treaty, the Paris Convention, and any other international arrangements,

Assignor will not execute any writing or do any act conflicting with the terms of this assignment,

Assignor will at any time upon request, without further or additional consideration, but at the expense of the Assignee, execute such additional assignments and other writings and do such additional acts as the Assignee may deem necessary or desirable to pursue the patent applications identified herein, including, but not limited to, rendering all necessary assistance in making applications for and obtaining patents that may issue thereon in the U.S. and any countries foreign to the U.S. on the invention, and in enforcing any rights accruing as a result of such applications or patents, by, for example, executing statements and other affidavits,

Assignor and Assignee agree the terms of this assignment shall bind, and inure to the benefit of, the legal representatives, successors, and assigns of all parties hereto,

Assignor authorizes Assignee to insert in this assignment the number and filing date of the application if the number and filing date of the application are not recited herein at the time of execution of this assignment by any or all of the parties hereto,

Assignor and Assignee agree that U.S. law governs this assignment, and

Assignee acknowledges and accepts this assignment.

IN WITNESS WHEREOF, Assignor has hereunder set his/her hand on the date shown below.

Date 17/11/2017

[Signature]  
Assignor: Walter CABRI

Date 17/11/2017

[Signature]  
Witness:

Date \_\_\_\_\_

\_\_\_\_\_  
Witness:

\*\*\*\*\*

Date 04 Dec 2017

Saswata Lahiri  
Assignor: Saswata LAHIRI

Date 04 Dec 2017

Witness  
Witness:

Date \_\_\_\_\_

Witness: \_\_\_\_\_

Date 04 Dec 2017

Bhuwan Bhaskar Mishra  
Assignor: Bhuwan Bhaskar MISHRA

Date 04 Dec 2017

Witness  
Witness:

Date \_\_\_\_\_

Witness: \_\_\_\_\_

Date 04 Dec 2017

Abul Azim  
Assignor: Abul AZIM

Date 04 Dec 2017

Witness  
Witness:

Date \_\_\_\_\_

Witness: \_\_\_\_\_

Date 04 Dec 2017

Nilendu Panda  
Assignor: Nilendu PANDA

Date 04 Dec 2017

Witness  
Witness:

Date \_\_\_\_\_

Witness: \_\_\_\_\_

Date 04 Dec. 2017

B. Poli Reddy  
Assignor: Poli Reddy BHAVANAM

Date 04 Dec. 2017

Vishal Sude  
Witness:

Date \_\_\_\_\_

Witness: \_\_\_\_\_

Date 04 Dec. 2017

Krishanra Roy  
Assignor: Krishanu RAY

Date 04 Dec. 2017

Vishal Sude  
Witness:

Date \_\_\_\_\_

Witness: \_\_\_\_\_

Date 04 Dec. 2017

Nikunj Kachhadia  
Assignor: Nikunj KACHHADIA

Date 04 Dec. 2017

Vishal Sude  
Witness:

Date \_\_\_\_\_

Witness: \_\_\_\_\_

Date 04 Dec. 2017

Kumber Singh  
Assignor: Kumber SINGH

Date 04 Dec. 2017

Vishal Sude  
Witness:

Date \_\_\_\_\_

Witness: \_\_\_\_\_